Inhibition of xenoreactive antibodies
US6572867B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 15, 1999 |
| Grant date | Jun 3, 2003 |
| Priority date | — |
| Expiry date | Apr 15, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/6093
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
One aspect of the present invention relates to methods and compositions for attenuating xenograft rejection by administering, to an animal receiving the xenograft, an amount of a polymer-derivatized xenoantigen (hereinafter “xenopolymer”) effective for inhibiting or lessening the severity of hyperacute rejection response (HAR), or other immunological response to the graft, that is dependent on the presence of the xenoantigen on the grafted tissues or cells. In certain embodiments, the xenopolymer is administered in an amount sufficient to neutralize host antibodies (“xenoreactive antibodies” or “XNA”) immunoreactive with the xenoantigen. The xenopolymer may additionally, or alternatively, be used as a tolerogen (or anergen) for the xenoantigen, e.g., able to suppress, to some degree, the production/secretion of XNAs by the immune system of the host.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.